India’s First mRNA-based COVID Vaccine HGCO19 Gets Approval For Next Phase of Clinical Trials

In a major breakthrough, India’s first mRNA-based COVID vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails. This was informed by the Department of Biotechnology (DBT) on Tuesday. As per reports, the Pune-based biotechnology company had submitted the interim clinical data of the vaccine’s Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO).

Leave a Reply

Your email address will not be published. Required fields are marked *

India’s First mRNA-based COVID Vaccine HGCO19 Gets Approval For Next Phase of Clinical Trials

In a major breakthrough, India’s first mRNA-based COVID vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails. This was informed by the Department of Biotechnology (DBT) on Tuesday. As per reports, the Pune-based biotechnology company had submitted the interim clinical data of the vaccine’s Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO).

Leave a Reply

Your email address will not be published. Required fields are marked *